Foundation For Neglected Disease Research

Data-driven R&D organisation solely dedicated to the research of infectious diseases

Social Impact

1 drug in clinical development
4 repurposed drug in development
100+ contract research projects completed

Solution

FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculous mycobacteria, malaria, dengue, leishmania, and serious bacterial infections, among others. Its COVID-19 late-stage clinical trials have been proven helpful in dealing with the pandemic. Its achievements in tuberculosis in vitro studies, animal efficacy models, and pharmacokinetic studies are well-noted. Our contract services include a fee-for-service mode to test therapeutics, vaccines, and other items. Thanks to the efforts of our scientists, as many as 13 new drugs are in preclinical development.

Problem

During the COVID-19 outbreak, the lack of data on clinical research was very evident. The world needs to learn from this grim chapter and be prepared to deal with novel viruses, bacteria, and infectious diseases. One of the best ways to deal with unforeseen disease outbreaks is by dedicating resources to cutting-edge R&D. The Foundation for Neglected Disease Research aims to conduct preclinical studies for various pathogens through several research programs.

Green Talks

Information